Biotechnology & Immunology


CRISPR/Cas9 Knockout Cell Lines and Lysates


Amsbio has established a comprehensive portfolio of knock-out cell lines and lysates generated with CRISPR/Cas9 technology. Using CRISPR/Cas9 gene editing technology for the generation of knock-out cell lines and cell lysates ensures the development of useful tools to validate antibody specificity and elucidate gene function. Knock-out cell lines and cell lysates are widely agreed to be the best negative controls to quickly and confidently prove an antibody’s specificity for a target of interest and ensure reproducibility.


Generated in the most widely used HEK293T, HeLa, and A549 cell lines, Amsbio gene edited homozygous knock-out cell lines work in the cells you know and trust. Consequently, you are no longer limited to highly specialised and altered backgrounds. Amsbio offers only 100% knock-out clonal lines meaning you don’t have to work with pools of cells containing only a percentage of knockout cells.


Knock-out cell lysates from Amsbio are made from double knock-out cell lines and provide the perfect negative control for Western Blots to validate the specificity of antibodies or be used in functional assays. Each Amsbio knock-out cell lysate product comes with a cell-line matched wild type control.


48427pr@reply-direct.com


Custom Cell Biology Services Offering Unique Manufacturing and Testing Capabilities Introduced


Lonza has introduced CellBio Services, a comprehensive portfolio of unique, custom solutions designed to meet specific, individual research application needs. Researchers across pharmaceutical and contract manufacturing organisations can now choose from an extensive range of services, including cell-line expansion and banking, media production, cell isolation, cell characterisation, transfection services, and 3-dimensional (3D) cell-culture services.


“For many years we’ve been leading the cell research market, with a broad offering of high-quality primary cells, media, reagents and devices,” said Andrew Winner, Product Manager for CellBio Services at Lonza Pharma Biotech & Nutrition. “CellBio Services has been established to expand this offering beyond the standard catalogue products and beyond what’s currently available on the market. Our customers can now benefit from unique manufacturing and testing capabilities, as well as Lonza’s access to the broadest tissue inventories, to unlock the next level of their research options.”


Lonza’s all-inclusive CellBio Services offering comprises: cell-line expansion and banking - cell lines can be expanded up to 10e10 and the cells can be cryopreserved in the preferred format; media production - manipulation of Lonza’s catalogue media products or production of new media, either in liquid or powder format; cell isolation - from a variety of tissues, including human, primate, porcine, canine, feline and murine; cell characterisation - development of cell-based assays for functional testing of recombinant proteins and small molecules; generation of recombinant cell lines - fast and convenient creation of recombinant cell lines overexpressing the gene of interest; 3D cell-culture services - the patented RAFT™ System is used to generate custom 3D cell culture systems, such as co-cultures and barrier models.


48789pr@reply-direct.com


Dual Impeller Single-Use Bioreactor System Released


Distek, Inc, a leading manufacturer of laboratory testing instruments for the pharmaceutical and biotechnology industry has added a Dual Impeller Single-Use Bioreactor System to their BIOne portfolio.


The dual impeller BIOne SUB increases mixing efficiency within the bioreactor resulting in an increased mass transfer coefficient (kLa); while maintaining the same rate of agitation.


“Optimised mammalian processes are yielding higher cell densities and more product than ever. We’ve developed a dual impeller SUB configuration to improve mixing efficiency and provide higher kLa values to support our customers as they develop tomorrow’s medicines and cures,” said Cristy Botens, Product Manager - Bioprocessing for Distek. 48790pr@reply-direct.com


Extended CRISPR Screening Service to Primary Human T Cells Announced


Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, has announced the extension of its CRISPR Screening Service to include ex vivo T lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery, enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.


CRISPR screens in primary T lymphocytes have proved challenging, owing to complex issues around the introduction of the screening components and Cas9 in particular. Horizon has adapted its established CRISPRko (knockout) platform to address these issues and to deliver a robust screening platform in human T lymphocytes, which will enable complex biological processes, novel targets and more effective drug therapies to be investigated in a therapeutically relevant cell type.


Horizon has added CRISPRko screens in ex vivo T lymphocytes to its established CRISPR screening formats – CRISPRko, CRISPRi (interference) and CRISPRa (activation) – in cancer cell lines. The Company’s extension of its CRISPRko Screening Service strengthens its existing immuno-oncology platform and reinforces its commitment to supporting researchers working in this rapidly growing field of research.


Terry Pizzie, Chief Executive Officer, Horizon Discovery Group, commented: “The successful demonstration of primary human T cells in Horizon’s CRISPR screening platforms is a breakthrough format for our clients working in the immuno-oncology space; enabling them to find gene targets and potential therapeutic avenues in an immediately biologically relevant setting rather than having to work through surrogate cell lines. We expect that this approach will allow our customers to save considerable time and resources in downstream validation, helping them to get therapeutics to the clinic faster.”


48145pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72